CD274 and neoplasm: In agreement with well-known limitations of anti-PD-L1 ICB for the treatment of solid tumors in general (74, 75) and the ineffectiveness of immunotherapy in pancreatic cancer specifically (76), in this study, PD-L1 blockade alone did not affect KPC tumor growth (Figure 2B).